Results 151 to 160 of about 729,378 (199)
Real-World Effectiveness of Bempedoic Acid in Reducing LDL-C: An Electronic Medical Records-Based Analysis. [PDF]
JACC AdvKatzmann JL +5 more
europepmc +1 more source
The High Burden of Dyslipidemia in Ibb, Yemen: A Retrospective Analysis From 2018 to 2026 of Gender and Age Associations in 14,691 Individuals. [PDF]
CureusAl-Hetar MAMY +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Baillière's Clinical Endocrinology and Metabolism, 1995
Lipoprotein (a) is similar to low-density lipoprotein but is unique in having an additional apolipoprotein called apolipoprotein (a) (apo(a)) covalently linked to it. apo(a), which is a member of the plasminogen gene superfamily, has a protease domain which cannot be activated to cause fibrinolysis.
A, Piolot, B, Jacotot
+7 more sources
Lipoprotein (a) is similar to low-density lipoprotein but is unique in having an additional apolipoprotein called apolipoprotein (a) (apo(a)) covalently linked to it. apo(a), which is a member of the plasminogen gene superfamily, has a protease domain which cannot be activated to cause fibrinolysis.
A, Piolot, B, Jacotot
+7 more sources
Current Opinion in Lipidology, 2014
Despite being both the longest known and the most prevalent genetic risk marker for atherosclerotic cardiovascular disease (CVD), little progress has been made in agreeing a role for lipoprotein (a) [Lp(a)] in clinical practice and developing therapies with specific Lp(a)-lowering activity.
Durrington, Paul N +3 more
openaire +4 more sources
Despite being both the longest known and the most prevalent genetic risk marker for atherosclerotic cardiovascular disease (CVD), little progress has been made in agreeing a role for lipoprotein (a) [Lp(a)] in clinical practice and developing therapies with specific Lp(a)-lowering activity.
Durrington, Paul N +3 more
openaire +4 more sources
JAMA
This JAMA Insights discusses lipoprotein(a), including factors associated with elevated lipoprotein(a) levels, how to manage them, and atherosclerotic cardiovascular disease risk.
Samia, Mora, Florian, Kronenberg
+6 more sources
This JAMA Insights discusses lipoprotein(a), including factors associated with elevated lipoprotein(a) levels, how to manage them, and atherosclerotic cardiovascular disease risk.
Samia, Mora, Florian, Kronenberg
+6 more sources
Current Opinion in Lipidology, 2016
Purpose of review Currently, different methods for extracorporeal elimination of atherogenic apolipoprotein B100 containing lipoprotein particles are used in clinical practice. Most of them effectively remove both lipoprotein(a) [Lp(a)] and LDL.
Sergei N, Pokrovsky +2 more
openaire +2 more sources
Purpose of review Currently, different methods for extracorporeal elimination of atherogenic apolipoprotein B100 containing lipoprotein particles are used in clinical practice. Most of them effectively remove both lipoprotein(a) [Lp(a)] and LDL.
Sergei N, Pokrovsky +2 more
openaire +2 more sources
Current Opinion in Lipidology, 2014
Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein. The metabolism of this lipoprotein is still not well understood.It has long been known that the plasma concentration of Lp(a) is highly heritable, with its genetic determinants located in the apo(a) locus and regulating the rate of hepatic apo(a) production.
Stefania, Lamon-Fava +2 more
openaire +2 more sources
Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein. The metabolism of this lipoprotein is still not well understood.It has long been known that the plasma concentration of Lp(a) is highly heritable, with its genetic determinants located in the apo(a) locus and regulating the rate of hepatic apo(a) production.
Stefania, Lamon-Fava +2 more
openaire +2 more sources
Lipoprotein(a): A Lipoprotein Whose Time Has Come
Current Treatment Options in Cardiovascular Medicine, 2017Cardiovascular disease is a leading cause of morbidity and mortality in the USA and around the world. While we are now able to achieve significant low-density lipoprotein cholesterol (LDL-C) lowering with current therapies, many patients remain at risk for cardiovascular disease (CVD). Elevated lipoprotein(a) [Lp(a)] has been shown to be an independent
Erik, Kelly, Linda, Hemphill
openaire +2 more sources